2.50
Hdl Handle:
http://hdl.handle.net/10033/621162
Title:
Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection.
Authors:
Debarry, Jennifer; Cornberg, Markus; Manns, Michael P
Abstract:
Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
Affiliation:
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.
Citation:
Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. 2017, 37 Suppl 1:67-72 Liver Int.
Journal:
Liver international : official journal of the International Association for the Study of the Liver
Issue Date:
Jan-2017
URI:
http://hdl.handle.net/10033/621162
DOI:
10.1111/liv.13320
PubMed ID:
28052625
Type:
Article
Language:
en
ISSN:
1478-3231
Appears in Collections:
publications of the scientific administration (GFW)

Full metadata record

DC FieldValue Language
dc.contributor.authorDebarry, Jenniferen
dc.contributor.authorCornberg, Markusen
dc.contributor.authorManns, Michael Pen
dc.date.accessioned2017-11-06T14:40:59Z-
dc.date.available2017-11-06T14:40:59Z-
dc.date.issued2017-01-
dc.identifier.citationChallenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. 2017, 37 Suppl 1:67-72 Liver Int.en
dc.identifier.issn1478-3231-
dc.identifier.pmid28052625-
dc.identifier.doi10.1111/liv.13320-
dc.identifier.urihttp://hdl.handle.net/10033/621162-
dc.description.abstractDespite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleChallenges in warranting access to prophylaxis and therapy for hepatitis B virus infection.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.en
dc.identifier.journalLiver international : official journal of the International Association for the Study of the Liveren

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.